Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +39.07%
#2 Siren Siren +30.71%
#3 Purr Purr +24.34%
#4 OriginTrail OriginTrail +16.72%
#5 UnifAI Network UnifAI Network +14.60%
#6 Tutorial Tutorial +14.15%
#7 Official Trump Official Trump +13.39%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.33%
#9 Prom Prom +11.74%
#10 Collect on Fanable Collect on Fanable +11.67%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Senhwa Biosciences, Inc. Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc.

6492
Rangering i aksjer #21774
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and... Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
Aksjekurs
$1.11
Sist synkronisert: 2026-08-21
Markedsverdi
$100.55M
Endring (1 dag)
-7.69%
Endring (1 år)
-7.17%
Land
TW
Handel Senhwa Biosciences, Inc. (6492)

Kategori

Healthcare
P/E-forhold for Senhwa Biosciences, Inc. (6492)
P/E-forhold per 2026 TTM: 0
Ifølge Senhwa Biosciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Senhwa Biosciences, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.